Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death
JAMA · 07.03.2023 · 329 (9) · 716
DOI: 10.1001/jama.2022.24388 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 07.03.2023. Verfasst von Anna Roca und 26 weiteren Autor:innen. Beteiligte Einrichtung: MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Neonatal Sepsis. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council.
Themen: Sepsis
Abstract (Originalsprache)
Importance Neonatal sepsis is a leading cause of neonatal mortality. New interventions are needed to decrease neonatal sepsis and mortality in regions with highest burden.
Objective
To evaluate the efficacy of intrapartum azithromycin to reduce neonatal sepsis or mortality, as well as neonatal and maternal infections. Design, Setting, and Participants This double-blind, placebo-controlled, randomized clinical trial enrolled and followed up birthing parents and their infants at 10 health facilities in The Gambia and Burkina Faso, West Africa, between October 2017 and May 2021.
Interventions
Participants were assigned at random to receive oral azithromycin (2 g) or placebo (ratio 1:1) during labor. Main Outcomes and Measures The primary outcome was a composite of neonatal sepsis or mortality, with the former defined based on microbiologic or clinical criteria. Secondary outcomes were neonatal infections (skin, umbilical, eye and ear infections), malaria, and fever; postpartum infections (puerperal sepsis, mastitis), fever, and malaria; and use of antibiotics during 4-week follow-up.
Results
The trial randomized 11 983 persons in labor (median age, 29.9 years). Overall, 225 newborns (1.9% of 11 783 live births) met the primary end point. The incidence of neonatal mortality or sepsis was similar in the azithromycin and placebo groups (2.0% [115/5889] vs 1.9% [110/5894]; risk difference [RD], 0.09 [95% CI, −0.39 to 0.57]), as was the incidence of neonatal mortality (0.8% vs 0.8%; RD, 0.04 [95% CI, −0.27 to 0.35]) and neonatal sepsis (1.3% vs 1.3%; RD, 0.02 [95% CI, −0.38 to 0.43]). Newborns in the azithromycin group compared with the placebo group had lower incidence of skin infections (0.8% vs 1.7%; RD, −0.90 [95% CI, −1.30 to −0.49]) and need for antibiotics (6.2% vs 7.8%; RD, −1.58 [95% CI, −2.49 to −0.67]). Postpartum parents in the azithromycin group had lower incidence of mastitis (0.3% vs 0.5%; RD, −0.24 [95% CI, −0.47 to −0.01]) and puerperal fever (0.1% vs 0.3%; RD, −0.19 [95% CI, −0.36 to −0.01]). Conclusions and Relevance Azithromycin administered orally during labor did not reduce neonatal sepsis or mortality. These results do not support routine introduction of oral intrapartum azithromycin for this purpose. Trial Registration ClinicalTrials.gov Identifier: NCT03199547
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
- Institut de Recherche en Sciences de la Santé-Clinical Research Unit of Nanoro (IRSS-CRUN), Nanoro, Burkina Faso.
- London School of Hygiene & Tropical Medicine, London, United Kingdom.
Förderung
- Medical Research Council
Zitieren
APA
Roca, A., Camara, B., Bognini, J. D., Nakakana, U. N., Somé, A. M., Beloum, N., Rouamba, T., Sillah, F., Danso, M., Jones, J. C., Graves, S., Jagne, I., Getanda, P., Darboe, S., Tahita, M. C., Ndure, E., Franck, H. S., Edmond, S. Y., Dondeh, B. L., …, & PregnAnZI-2 Working Group (2023). Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death. JAMA, 329(9), 716. https://doi.org/10.1001/jama.2022.24388
Vancouver
Roca A, Camara B, Bognini JD, Nakakana UN, Somé AM, Beloum N, et al. Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death. JAMA. 2023;329(9):716. doi:10.1001/jama.2022.24388
BibTeX
@article{Roca2023,
author = {Roca, Anna and Camara, Bully and Bognini, Joel D and Nakakana, Usman N and Somé, Athasana M and Beloum, Nathalie and Rouamba, Toussaint and Sillah, Fatoumata and Danso, Madikoi and Jones, Joquina C and Graves, Shashu and Jagne, Isatou and Getanda, Pauline and Darboe, Saffiatou and Tahita, Marc C and Ndure, Ebrahim and Franck, Hien S and Edmond, Sawadogo Y and Dondeh, Bai L and Nassa, Wilfried G J and Garba, Zakaria and Bojang, Abdoulie and Njie, Yusupha and Bottomley, Christian and Tinto, Halidou and D'Alessandro, Umberto and PregnAnZI-2 Working Group, PregnAnZI-2 Working Group},
title = {Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death},
journal = {JAMA},
year = {2023},
volume = {329},
number = {9},
pages = {716},
doi = {10.1001/jama.2022.24388}
}
EUVIMED